11.11.2024 23:31:20 CET | Aqua Bio Technology ASA | Additional regulated information required to be disclosed under the laws of a member state

Reference is made to the notice for an extraordinary general meeting in Aqua Bio Technology ASA (the "Company") published on 23 October 2024, and to the private placement of new shares in the Company (the "Private Placement") that was announced placed on 18 October, and to the contemplated subsequent offering of new shares following the Private Placement (the "Subsequent Offering").

The Company's auditor has prepared an independent expert report in connection with the Private Placement, which is attached to this stock exchange notice, and forms part of the decision material for the general meeting. In connection with the Private Placement, the Board has also amended its proposal with respect to the Private Placement where the share capital shall be increased with NOK 98,408,672.50 through issuance of 39,363,469 new shares, i.e. one share less than stated in the notice for the extraordinary general meeting. The reason for the amended proposal is an updated counting of certain receivables to be converted to new shares in the Private Placement.

Further, the Board of the Company has decided to withdraw the proposal for share capital increase in connection with the Subsequent Offering of up to 2,000,000 new shares, as in the period following announcement of the Private Placement it has been traded more than 2,000,000 shares in the Company over the stock exchange and at lower average prices than the subscription price in the Subsequent Offering of NOK 3 per share. Shareholders that have wanted to limit their dilution following the Private Placement has thus been able to do so through purchase of shares in the open market.

For further information, please contact Jan Varming, CFO, telephone +47 90 83 90 76.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skincare products. ABT's cosmetics ingredients are highly effective, and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skincare products developed by partners towards consumers and professional users. ABT's focus on commercialization and development of natural ingredients and natural skincare products has been, and will continue to be, an important part of the Company's strategy going forward. ABT is listed on the Euronext Expand market of the Oslo Stock Exchange.

Disclosure regulation

This information is subject of the disclosure requirements pursuant to section of 5-12 of the Norwegian Securities Trading Act.

Contacts

• Jan Aas Varming, CFO, Aqua Bio Technology ASA, +47 908 39 076, jan@aquabiotech.no

About Aqua Bio Technology ASA

Aqua Bio Technology (ABT) is developing and commercializing sustainable
biotechnology for use in skin care products. ABT's cosmetics ingredients are
highly effective and they provide the cosmetics industry with natural
alternatives to traditional ingredients. ABT is also marketing and distributing
natural skin care products developed by partners towards consumers and
professional users. Aqua Bio Technology is listed on Euronext Expand.

Attachments

• Download announcement as PDF.pdf
• Sakkyndig_redegjorelse_ved_kapitalforhoyelse_ved_motregning_Aqua_Bio_Technology_ASA_11-11-2024.pdf